Statin safety: a systematic review.

By M. Law, Alicja R. Rudnicka. American Journal of Cardiology, 2006

805 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Nutrition and Dietetics, Surgery

View Paper: https://www.semanticscholar.org/paper/c10231ffe7a131bc5f981089a67e68ffd19996ee

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

In Nutrition and Dietetics

In Surgery

Citations in the corpus

Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. (2007, background): “Nonetheless, available evidence has shown that the incidence of adverse drug reactions is relatively low, generally occurs during the early rather than late phases of therapy, and is unlikely to entirely account for nonadherence, especially to statins or other preventive therapies.(32,33)”
Cholesterol induces CD8+ T-cell exhaustion in the tumor microenvironment (2019, positive): “Statins are one of the main compounds that inhibit the rate-limiting enzyme in cholesterol synthesis and are commonly used cholesterol-lowering medications with a high safety profile (Law and Rudnicka, 2006).”
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “The frequency of rhabdomyolysis has been estimated to represent 1 3 cases/100 000 patient-years.(235) Patients taking statin therapy frequently report muscle symptoms [so-called ‘statin-associated muscle symptoms’ (SAMS)], and in nonrandomized, observational studies, statins are associated with musc”
Interpretation of the evidence for the efficacy and safety of statin therapy. (2016, background): “Approved statin regimens have been associated both in observational studies and in randomized trials with large relative risks for myopathy,(141,150,216) but typically with small absolute excesses (about 1 case per 10,000 people treated per year) and even smaller excesses in the incidence of rhabdom”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “100,131 Secondary targets have also been defined by inference for nonHDL-C and for apoB; they receive a moderate grading, as they have not been extensively studied in RCTs. Clinicians who are using apoB in their practice can use targets levels of <100 mg/dL and <80 mg/ dL for subjects at high or at ”
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015, neutral): “The incidence of rhabdomyolysis in association with statin therapy is 1 in 100 000 per year.(7) In view of the rarity of CK elevations during statin therapy, it is not recommended”
Dissemination and publication of research findings: an updated review of related biases. (2010, background): “Pittler et al. (2000) identified 19 systematic reviews that included 351 controlled trials of complementary medicine.”
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. (2011, methodology): “Average, untreated LDL cholesterol levels are about 220 mg/dL in those with FH and serum total cholesterol levels are often in the range of 350-550 mg/dL; the risk of premature CHD is elevated about 20-fold without treatment.(10,24) The excess risk for CHD has been estimated to be as high as 100-fol”